Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T44008
(Former ID: TTDI01166)
|
|||||
Target Name |
cAMP formation (cAMP form)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Mild neurocognitive disorder [ICD-11: 6D71] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | UCB-11056 | Drug Info | Phase 2 | Cognitive impairment | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | UCB-11056 | Drug Info | [1], [2] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61. | |||||
REF 2 | Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.